The Sample Taken Before Sydney: Peres Jepchirchir, EPO's Narrow Window, and an Unfinished File

At 2:18:31 on the morning of 30 August 2026, the clock stopped in Sydney. Peres Jepchirchir had put more than three minutes between herself and her compatriot Irene Chepet Cheptai — and in the marathon, three minutes is the gap coaches sometimes call "the second race", meaning the win does not tell you that somebody ran abnormally fast, only that the field ran slow that day. I saved the results sheet that evening, as I do after every big race.

A few weeks later, another sheet had to be laid on top of it: a provisional suspension notice from the Athletics Integrity Unit. An out-of-competition sample from the 33-year-old had tested positive for erythropoietin (EPO). The sample was not collected in Sydney. It was collected in Kenya, before the race. That is the detail commentary loses first — the title under discussion was won after the sample was taken. So the question is not what she took. The question is who keeps the account of the weeks between the collection date and the finish line.

It needs saying plainly that Jepchirchir's career was built on a start list, not a suspicion. She won the Olympic women's marathon at Tokyo 2026 and returned to the same Japanese capital in September 2026 to take the World Championships title. She broke the women's half-marathon world record in 2026 and broke it three more times in 2026. Away from Sydney her major wins are the New York Marathon 2026, the Boston Marathon 2026 and the London Marathon 2026. Sydney is the race that became the seventh World Marathon Major in 2026 — which means the event is losing, in its first years as a Major, exactly the champion it wanted for its brand.

I was in the National Stadium in Tokyo in September 2026 when she won that title. The humidity that evening was such that the physio standing at the edge of the track had his shirt stuck to his back, and I was writing in my notebook not just the temperature but which athletes walked to the ice tubs unaided and which needed two people. That is where my most basic understanding of the marathon was formed: in this event the body's real enemy is not speed, it is heat and the gap between recoveries.

EPO is the drug of that gap. It is a natural hormone produced in the kidney that signals the bone marrow to manufacture new red blood cells. Injected from outside, it raises red-cell mass, increases the oxygen delivered to muscle, and postpones fatigue. In a marathon its benefit is not pace. Its benefit is that the body keeps clearing lactate past forty kilometres and stands up again quickly between races. EPO is not the drug of speed in the marathon; it is the drug of the calendar.

Catching it is just as awkward. The presence of recombinant EPO in urine is visible only inside a short window — some of the literature puts it at three to four days. A blood test offers a different kind of evidence; the Athlete Biological Passport reads months-long trends in haemoglobin and reticulocytes rather than a single injection. That is why a positive urine sample arrives with an unavoidable question attached: on which day was it collected, and why is there no blood sample from the weeks before it.

On WADA's Prohibited List, EPO sits in class S2 — peptide hormones, growth factors and mimetics. It is banned at all times, in competition and out. Because it is a non-specified substance, a provisional suspension becomes mandatory; that is why the AIU announced a suspension before any finding. A first violation carries a standard sanction of four years unless the athlete can establish that the use was not intentional. The B sample, the hearing, and then a possible appeal to CAS — that journey is measured in years, not months.

I came for the economics; I stayed for the medicals. And in the medical room the scoreboard disappears and the body speaks — in the anti-doping lab the same thing happens, except the body doing the speaking is a sample, not an athlete.

Now the part no press release will carry. Three major marathons in twenty-eight months — London in April 2026, the Tokyo World Championships in September 2026, Sydney in August 2026. Thirty-three is not the summit of the marathon; it is the last stair to it. At that age the body's problem is not that it cannot run fast; the problem is that it no longer repairs itself between races at the speed it once did. And when the Olympic gold, the world title and three of the majors are already in the cabinet, no target is left on the track — the only remaining target is the calendar. Winning the first edition of a newly minted seventh Major is a different kind of asset, commercially and in ranking terms.

The first page of a medical file never begins with a sanction; it begins with a dose. EPO's window is so narrow that a positive sample almost always points to a recent, planned dose administered under somebody's supervision — it does not arrive by accident from a powder. This is where a defence is really tested: the clinic record, the injection log, the prescription, the name of the medical staff in the camp. Among the bans that fell on India's 4x400 relay women in 2026, one case turned on an over-the-counter powder bought near the Patiala camp. The sanction did not follow because a conspiracy was proved; it followed because no receipt, no prescription and no record of the source could be produced. A failed medical is not a verdict; it is a document. So is a positive test.

The second page belongs to the Sydney result, and it should be read through the rulebook, not through politics. Results from the date of sample collection onward can be annulled — which means that 2:18:31, the prize money attached to it, the Abbott World Marathon Majors standing and the ranking points all now sit with a panel. The Tokyo 2026 title does not automatically come into question; it does only if the biological passport points backwards. A single positive sample and a pattern do not sit on the same sheet of paper, and that difference will decide whether this remains the story of one race or becomes the story of a career.

There is a third page nobody writes. Who pays for EPO. Thicker blood does not mean only more oxygen. In a marathon the body loses plasma through sweat, haematocrit climbs further, viscosity rises. The bill is settled in the last ten kilometres — cramp, a rhythm breaking suddenly, and the dead week that follows, which we usually dismiss as training load. I keep a file on every marathon body, and the file always starts with a question; here the question is how much of that three-minute gap in Sydney belonged to the legs and how much to the blood.

The easiest response to this story is the one that arrives in the first week of every doping item: deliver the verdict. I am against it, and not merely because a provisional suspension is not a finding. I am against it because this case contains something that looks inverted at first glance — an athlete with nothing left to win also had nothing left to lose, so the ordinary logic of motive does not apply. In the marathon, schedule takes the place of motivation. And the pressure of that schedule is not one athlete's moral crisis; it is the architecture of the sport — seven Majors, ranking points, contract clauses and an expectation that champions appear every season. The anti-doping system catches the bargain a body strikes with a calendar. The body pays the penalty; the calendar is never audited.

The second inversion is that the heaviest damage here falls on a race that did nothing wrong. Sydney became the seventh World Marathon Major in 2026, and what a newly elevated race needs most is its start list and its champion. If its first winner disappears under an open case, the question that follows is how rigorous pre-race testing is at new Majors and who audits it. That question belongs not to a race director but to the system that hands out Major status.

The third inversion is geographical, and it is the one I have been keeping paper on since 2026. The sample was collected in Kenya, before the race, out of competition. It was collected where the density of talent is highest and the density of monitoring is not. Kenya has built laws, task forces and faster investigations over the past few years — and faster investigation has one direct consequence: what was once missed now gets caught. The picture is clear that the system worked; it is not clear who inside the system is teaching whom. Both things can be true at once, and both should be written at once.

As for what comes next, the file rests on three dates. The result of the B sample; the date of the hearing; and, if it goes to CAS, the constitution of the panel. Anything said between those three — by an agent, a federation, a sponsor — is not part of the file. I learned that discipline in 2026, when a two-line agency item forced me to read an entire arbitration award, and I understood that the basis of a sentence that makes headlines usually sits on the fifteenth page of a document.

When this file closes, we will know whose three minutes those were in Sydney — the legs', the blood's, or simply the field's that day. Until then one thing is settled: the fastest stories ever written about a marathon body are decided not in a stadium but in a quiet room far from one. And that room has no scoreboard.